Chemoresistance is a serious limitation of cancer treatment1. Until recently, almost all the work done to study this limitation has been restricted to tumour cells2. Here we identify a novel molecular mechanism by which endothelial cells regulate chemosensitivity. We establish that specific targeting of focal adhesion kinase (FAK; also known as PTK2) in endothelial cells is sufficient to induce tumour-cell sensitization to DNA-damaging therapies and thus inhibit tumour growth in mice. The clinical relevance of this work is supported by our observations that low blood vessel FAK expression is associated with complete remission in human lymphoma. Our study shows that deletion of FAK in endothelial cells has no apparent effect on blood vessel function per se, but induces increased apoptosis and decreased proliferation within perivascular tumour-cell compartments of doxorubicin- and radiotherapy-treated mice. Mechanistically, we demonstrate that endothelial-cell FAK is required for DNA-damage-induced NF-κB activation in vivo and in vitro, and the production of cytokines from endothelial cells. Moreover, loss of endothelial-cell FAK reduces DNA-damage-induced cytokine production, thus enhancing chemosensitization of tumour cells to DNA-damaging therapies in vitro and in vivo. Overall, our data identify endothelial-cell FAK as a regulator of tumour chemosensitivity. Furthermore, we anticipate that this proof-of-principle data will be a starting point for the development of new possible strategies to regulate chemosensitization by targeting endothelial-cell FAK specifically.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , & Cancer: Principles and Practice of Oncology (Lippincott Williams and Wilkins, 2001)

  2. 2.

    & Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updat. 11, 51–60 (2008)

  3. 3.

    et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012)

  4. 4.

    et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012)

  5. 5.

    et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Med. 18, 1359–1368 (2012)

  6. 6.

    et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488–503 (2012)

  7. 7.

    & DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355–366 (2010)

  8. 8.

    et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165–178 (2012)

  9. 9.

    et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171–185 (2013)

  10. 10.

    & Integrin-regulated FAK–Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516–523 (2006)

  11. 11.

    et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J. Cell Biol. 197, 907–919 (2012)

  12. 12.

    et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 18, 2998–3003 (2004)

  13. 13.

    & Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290–10295 (2009)

  14. 14.

    et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med. 2, 516–528 (2010)

  15. 15.

    et al. Biphasic function of focal adhesion kinase in endothelial tube formation induced by fibril-forming collagens. Biochem. Biophys. Res. Commun. 374, 699–703 (2008)

  16. 16.

    et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 10, 2135–2145 (2011)

  17. 17.

    et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med. 328, 1002–1006 (1993)

  18. 18.

    Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother. Pharmacol. 49 (suppl. 1). 13–20 (2002)

  19. 19.

    et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436–448 (2008)

  20. 20.

    The diverse and complex roles of NF-κB subunits in cancer. Nature Rev. Cancer 12, 121–132 (2012)

  21. 21.

    et al. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-κB signaling in intestinal epithelial cells. Am. J. Physiol. Cell Physiol. 290, C1310–C1320 (2006)

  22. 22.

    , & FAK activation is required for TNF-α-induced IL-6 production in myoblasts. J. Cell. Physiol. 223, 389–396 (2010)

  23. 23.

    et al. Focal adhesion kinase modulates activation of NF-κB by flow in endothelial cells. Am. J. Physiol. Cell Physiol. 297, C814–C822 (2009)

  24. 24.

    et al. Tumor necrosis factor-induced nuclear factor κB activation is impaired in focal adhesion kinase-deficient fibroblasts. J. Biol. Chem. 278, 29359–29365 (2003)

  25. 25.

    & Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunol. 12, 715–723 (2011)

  26. 26.

    , & NF-κB and the link between inflammation and cancer. Immunol. Rev. 246, 379–400 (2012)

  27. 27.

    et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004)

  28. 28.

    & Primary mouse endothelial cell culture for assays of angiogenesis. Methods Mol. Med. 120, 503–509 (2006)

  29. 29.

    et al. Establishment of murine cell lines by constitutive and conditional immortalization. J. Biotechnol. 120, 99–110 (2005)

  30. 30.

    , & p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12, 15–25 (2003)

Download references


We thank A. Papachristodoulou, J. Holdsworth and B. Williams for their help with immunostaining and animal husbandry. Also M. Hemann for his critical appraisal of the manuscript. The work was funded by CR-UK (C9218/A12007), AICR (12-1068), Medical Research Council (G0901609), National Cancer Institute (P01 CA95426:JGG); Leukemia Lymphoma Research (11022); and CR-UK PhD studentship (C1443/A9215).

Author information

Author notes

    • Louise E. Reynolds
    • , Silvia Batista
    • , Fevzi Demircioglu
    • , Isabelle Fernandez
    • , Tanguy Lechertier
    • , Delphine M. Lees
    •  & Ping-Pui Wong

    These authors contributed equally to this work.


  1. Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

    • Bernardo Tavora
    • , Louise E. Reynolds
    • , Silvia Batista
    • , Fevzi Demircioglu
    • , Isabelle Fernandez
    • , Tanguy Lechertier
    • , Delphine M. Lees
    • , Ping-Pui Wong
    • , Annika Alexopoulou
    •  & Kairbaan M. Hodivala-Dilke
  2. Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

    • George Elia
  3. Centre for Haemato-Oncology, Barts Cancer Institute, CR-UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

    • Andrew Clear
    •  & John G. Gribben
  4. Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK

    • Adeline Ledoux
    • , Jill Hunter
    •  & Neil Perkins


  1. Search for Bernardo Tavora in:

  2. Search for Louise E. Reynolds in:

  3. Search for Silvia Batista in:

  4. Search for Fevzi Demircioglu in:

  5. Search for Isabelle Fernandez in:

  6. Search for Tanguy Lechertier in:

  7. Search for Delphine M. Lees in:

  8. Search for Ping-Pui Wong in:

  9. Search for Annika Alexopoulou in:

  10. Search for George Elia in:

  11. Search for Andrew Clear in:

  12. Search for Adeline Ledoux in:

  13. Search for Jill Hunter in:

  14. Search for Neil Perkins in:

  15. Search for John G. Gribben in:

  16. Search for Kairbaan M. Hodivala-Dilke in:


The following authors are listed in the author list in alphabetical order: S.B., F.D., I.F., T.L., D.M.L. and P.-P.W. for their equal and combined contribution to the paper. B.T. and K.M.H.-D. designed the experiments. B.T. performed the experiments. L.E.R. did the GM-CSF rescue experiments in vivo, vessel perfusion, doxorubicin delivery, p-STAT3 staining and hypoxia assays. S.B. performed some of the tumour growth and treatment experiments, CD45 analysis, human lymphoma staining and irradiated cytokine responses; F.D. carried out the conditioned media experiments and MTS assays and several histological analyses; I.F. conducted the primary endothelial cell assays; T.L. measured endothelial-cell FAK and blood-vessel FAK levels in human lymphoma; D.M.L. did the transfections and nuclear fractionation experiments; P.-P.W. carried out the transfected cell cytokine arrays. G.E. carried out the histology; A.C. and J.G.G. provided human lymphoma tissue sections and advice; A.L., J.H. and N.P. performed the NF-κB activation assays and A.A. carried out the survival analysis. B.T. and K.M.H.-D. wrote the paper with substantial input from the co-authors.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Kairbaan M. Hodivala-Dilke.

Extended data

About this article

Publication history







By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.